Related Experiment Video
Updated: Jun 21, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
GQIcombi application to subdue glioma via differentiation therapy
Varvara Kolesnikova1, Alexander Revishchin1, Lika Fab1
1Laboratory of Neurogenetics and Genetics Development, Institute of Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences (RAS), Moscow, Russia.
Abstract:
Current therapy protocols fail to cure high-grade gliomas and prevent recurrence. Therefore, novel approaches need to be developed. A re-programing of glioma cell fate is an alternative attractive way to stop tumor growth. The two-step protocol applies the antiproliferative GQ bi-(AID-1-T) and small molecule inducers with BDNF to trigger neural differentiation into terminally differentiated cells, and it is very effective on GB cell cultures. This original approach is a successful example of the "differentiation therapy". To demonstrate a versatility of this approach, in this publication we have extended a palette of cell cultures to gliomas of II, III and IV Grades, and proved an applicability of that version of differential therapy for a variety of tumor cells. We have justified a sequential mode of adding of GQIcombi components to the glioma cells. We have shown a significant retardation of tumor growth after a direct injection of GQIcombi into the tumor in rat brain, model 101/8. Thus, the proposed strategy of influencing on cancer cell growth is applicable to be further translated for therapy use.
Insights
This study introduces a novel differentiation therapy for high-grade gliomas, reprogramming cancer cells into non-proliferative neurons. This approach shows promise in reducing tumor growth and offers a new therapeutic strategy.
Area of Science:
- Neuro-oncology
- Cancer cell biology
- Drug discovery
Background:
- Current high-grade glioma therapies are insufficient, leading to tumor recurrence.
- Reprogramming glioma cell fate offers a novel therapeutic strategy.
- Differentiation therapy aims to halt tumor growth by inducing terminal cell differentiation.
Purpose of the Study:
- To evaluate a novel two-step differentiation therapy protocol for various glioma grades.
- To demonstrate the versatility and efficacy of this approach in different glioma cell cultures.
- To assess the therapeutic potential of this strategy in a preclinical rat brain tumor model.
Main Methods:
- A two-step protocol using antiproliferative GQ bi-(AID-1-T) and BDNF-induced neural differentiation.
- Application of the protocol to glioma cell cultures of Grades II, III, and IV.
- Direct injection of the GQIcombi formulation into rat brain tumors (model 101/8).
Main Results:
- The protocol effectively induced neural differentiation in glioma cell cultures.
- Significant tumor growth retardation was observed after direct GQIcombi injection in a rat model.
- The differentiation therapy proved effective across a range of glioma cell types.
Conclusions:
- The developed differentiation therapy is a versatile and effective strategy against gliomas.
- This approach shows potential for translation into clinical therapy for glioma treatment.
- Reprogramming cancer cell fate represents a promising avenue for novel glioma treatments.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
05:45Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024